How GlaxoSmithKline Lost Nearly $10B in October Post author:Sam Post published:November 9, 2017 Post category:BioPharma Could GlaxoSmithKline’s industry-leading dividend be at risk? Source: BioSpace You Might Also Like Eli Lilly’s Verzenio Picks Up Third Approved Indication February 26, 2018 FDA Calls Novartis' Melanoma Combo Drug a Breakthrough October 22, 2017 <b>Spruce Biosciences</b> Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program October 11, 2017
<b>Spruce Biosciences</b> Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program October 11, 2017
